JP2020502140A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020502140A5 JP2020502140A5 JP2019531895A JP2019531895A JP2020502140A5 JP 2020502140 A5 JP2020502140 A5 JP 2020502140A5 JP 2019531895 A JP2019531895 A JP 2019531895A JP 2019531895 A JP2019531895 A JP 2019531895A JP 2020502140 A5 JP2020502140 A5 JP 2020502140A5
- Authority
- JP
- Japan
- Prior art keywords
- plasminogen
- use according
- pharmaceutical composition
- subject
- levels
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2016/110171 | 2016-12-15 | ||
| CNPCT/CN2016/110171 | 2016-12-15 | ||
| PCT/CN2017/089062 WO2018107702A1 (zh) | 2016-12-15 | 2017-06-19 | 一种治疗糖尿病的新方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020502140A JP2020502140A (ja) | 2020-01-23 |
| JP2020502140A5 true JP2020502140A5 (enExample) | 2020-07-30 |
| JP7171572B2 JP7171572B2 (ja) | 2022-11-15 |
Family
ID=62557852
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019532043A Active JP7554048B2 (ja) | 2016-12-15 | 2017-06-19 | インスリン分泌を促進する方法 |
| JP2019532019A Active JP7554557B2 (ja) | 2016-12-15 | 2017-06-19 | インスリン受容体基質－２の発現を促進する方法 |
| JP2019532017A Active JP7175270B2 (ja) | 2016-12-15 | 2017-06-19 | グルカゴン、インスリンを正常なバランスに戻らせる方法 |
| JP2019531895A Active JP7171572B2 (ja) | 2016-12-15 | 2017-06-19 | 糖尿病を治療するための新しい方法 |
| JP2022119582A Pending JP2022166028A (ja) | 2016-12-15 | 2022-07-27 | インスリン受容体基質－２の発現を促進する方法 |
| JP2022119543A Pending JP2022166026A (ja) | 2016-12-15 | 2022-07-27 | グルカゴン、インスリンを正常なバランスに戻らせる方法 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019532043A Active JP7554048B2 (ja) | 2016-12-15 | 2017-06-19 | インスリン分泌を促進する方法 |
| JP2019532019A Active JP7554557B2 (ja) | 2016-12-15 | 2017-06-19 | インスリン受容体基質－２の発現を促進する方法 |
| JP2019532017A Active JP7175270B2 (ja) | 2016-12-15 | 2017-06-19 | グルカゴン、インスリンを正常なバランスに戻らせる方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022119582A Pending JP2022166028A (ja) | 2016-12-15 | 2022-07-27 | インスリン受容体基質－２の発現を促進する方法 |
| JP2022119543A Pending JP2022166026A (ja) | 2016-12-15 | 2022-07-27 | グルカゴン、インスリンを正常なバランスに戻らせる方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US11129880B2 (enExample) |
| EP (4) | EP3556392B1 (enExample) |
| JP (6) | JP7554048B2 (enExample) |
| CN (4) | CN110139667A (enExample) |
| CA (4) | CA3047177A1 (enExample) |
| DK (1) | DK3556383T5 (enExample) |
| ES (1) | ES2981141T3 (enExample) |
| TW (7) | TWI669130B (enExample) |
| WO (7) | WO2018107706A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI624267B (zh) | 2015-12-18 | 2018-05-21 | Talengen Institute Of Life Sciences Co Ltd | 纖溶酶原在製備預防或治療糖尿病性視網膜病變的藥劑上的用途及包括纖溶酶原用於預防或治療糖尿病性視網膜病變之藥劑 |
| TWI653981B (zh) | 2015-12-18 | 2019-03-21 | 深圳瑞健生命科學硏究院有限公司 | Use of plasminogen for the preparation of a medicament for preventing or treating a condition associated with diabetic nerve injury |
| CN108778307A (zh) | 2015-12-18 | 2018-11-09 | 泰伦基国际有限公司 | 一种预防和治疗糖尿病肾病的方法 |
| US11338022B2 (en) | 2015-12-18 | 2022-05-24 | Talengen International Limited | Method for preventing and treating angiocardiopathy |
| US11129880B2 (en) * | 2016-12-15 | 2021-09-28 | Talengen International Limited | Method for promoting insulin secretion |
| US11219669B2 (en) | 2016-12-15 | 2022-01-11 | Talengen International Limited | Method for preventing and treating liver fibrosis |
| US11938172B2 (en) | 2017-06-19 | 2024-03-26 | Talengen International Limited | Method for regulating and controlling GLP-1/GLP-1R and drug |
| CN111411072B (zh) * | 2020-03-09 | 2022-10-11 | 同济大学 | SLC30A8基因表达下调的抗糖尿病胰岛β细胞及其应用 |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| GB8721951D0 (en) | 1987-09-18 | 1987-10-28 | Thrombosis Research Trust | Organic compounds |
| JP2764264B2 (ja) | 1987-10-01 | 1998-06-11 | 株式会社ミドリ十字 | 線溶活性増強剤 |
| AU4661493A (en) | 1992-07-01 | 1994-01-31 | Beth Israel Hospital Boston | Enhancement of thrombolytic therapy with deglycosylated plasminogen |
| DK125693D0 (enExample) | 1993-11-05 | 1993-11-05 | Novo Nordisk As | |
| DE4411143C2 (de) | 1994-03-30 | 1996-08-01 | Immuno Ag | Thrombosemittel |
| BR9608326A (pt) | 1995-04-26 | 2000-03-08 | Childrens Medical Center | Fragmentos de angiostatina e angiostatina agregada e processos de uso. |
| CA2226575C (en) | 1995-07-27 | 2011-10-18 | Genentech, Inc. | Stabile isotonic lyophilized protein formulation |
| US5955627A (en) | 1996-12-16 | 1999-09-21 | Kuraray Co., Ltd. | Process for the preparation of cyclopropylacetylene derivatives |
| JP2002510209A (ja) * | 1997-06-26 | 2002-04-02 | カロリンスカ イノベイションズ アクチボラゲット | インビボで血管形成を調節することができるプラスミノーゲンのクリングルドメイン１−５ |
| JP3561154B2 (ja) | 1997-12-26 | 2004-09-02 | 株式会社東芝 | 放送受信装置および契約管理装置 |
| US6728260B2 (en) | 1998-06-26 | 2004-04-27 | Intel Corporation | Switch and/or router unit |
| WO2000018436A1 (en) | 1998-09-29 | 2000-04-06 | Leuven Research & Development Vzw | Use of compounds that reduce alpha2-antiplasmin in vivo for the preparation of a composition for the treatment of ischemic stroke |
| WO2000044391A2 (en) | 1999-01-28 | 2000-08-03 | The Children's Medical Center Corporation | Plasminogen kringle 4 region fragments and methods of use |
| US6899877B2 (en) | 1999-03-09 | 2005-05-31 | Minu, L.L.C. | Process for generating plasmin in the vitreous of the eye and inducing separation of the posterior hyaloid from the retina |
| US6733750B1 (en) | 1999-03-09 | 2004-05-11 | Minu, L.L.C. | Process and composition for inducing posterior vitreous detachment |
| US20030014787P1 (en) | 1999-03-31 | 2003-01-16 | Olesen L. Pernille | Floribunda rose variety 'POULfeld' |
| CA2385703A1 (en) | 1999-10-07 | 2001-04-12 | Human Genome Sciences, Inc. | Plasminogen-like polynucleotides, polypeptides, and antibodies |
| US6964764B2 (en) | 1999-11-13 | 2005-11-15 | Talecris Biotherapeutics, Inc. | Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin |
| US20020159992A1 (en) | 2000-09-29 | 2002-10-31 | Jack Henkin | Antiangiogenic polypeptides and methods for inhibiting angiogenesis |
| TWI224101B (en) | 2001-06-20 | 2004-11-21 | Wyeth Corp | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) |
| TWI240723B (en) | 2001-06-20 | 2005-10-01 | Wyeth Corp | Substituted naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) |
| US6596785B2 (en) | 2001-07-17 | 2003-07-22 | Foamex L.P. | Ink retaining foam structure |
| US7067492B2 (en) | 2001-09-06 | 2006-06-27 | Omnio Ab | Method of promoting healing of a tympanic membrane perforation |
| US20030198666A1 (en) | 2002-01-07 | 2003-10-23 | Richat Abbas | Oral insulin therapy |
| US7202066B2 (en) | 2002-01-29 | 2007-04-10 | Carrington Laboratories, Inc. | Combination of a growth factor and a protease enzyme |
| JP2005525798A (ja) | 2002-02-06 | 2005-09-02 | トロムスドルフ ゲーエムベーハー ウント コー．カーゲー アルツナイミッテル | 微生物内での組み換えタンパク質の生産方法 |
| US6787135B2 (en) | 2002-03-13 | 2004-09-07 | William Beaumont Hospital | Modification of vitreal matrix metalloproteinase activity |
| EP1576137A4 (en) | 2002-10-29 | 2010-06-30 | Genentech Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES |
| GB0228409D0 (en) | 2002-12-06 | 2003-01-08 | Thromb X Nv | Pharmacological vitreolysis |
| CN1451746A (zh) | 2003-03-20 | 2003-10-29 | 广州市启源生物科技有限公司 | 人纤溶酶原Kringle 5缺失突变重组多肽 |
| US7075933B2 (en) | 2003-08-01 | 2006-07-11 | Nortel Networks, Ltd. | Method and apparatus for implementing hub-and-spoke topology virtual private networks |
| JP4740531B2 (ja) | 2003-09-30 | 2011-08-03 | 雪印乳業株式会社 | 骨吸収抑制剤 |
| US20050250694A1 (en) * | 2003-10-10 | 2005-11-10 | Ma Jian-Xing | Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same |
| CN1946352A (zh) | 2004-04-09 | 2007-04-11 | 狄科特康坦特公司 | 递送药物至眼以治疗后段疾病的方法和物品 |
| MXPA06012236A (es) | 2004-04-22 | 2007-01-31 | Talecris Biotherapeutics Inc | Plasmina modificada en forma recombinante. |
| US7754747B2 (en) | 2004-08-23 | 2010-07-13 | Wyeth Llc | Oxazolo-naphthyl acids |
| JP2008510814A (ja) | 2004-08-23 | 2008-04-10 | ワイス | Ｐａｉ−１阻害剤としてのピロロ−ナフチル酸 |
| CN101227918A (zh) | 2005-04-29 | 2008-07-23 | 加州大学评议会 | 治疗以炎症反应为特征的病理的肽和肽模拟物 |
| US20060257391A1 (en) | 2005-05-11 | 2006-11-16 | Bausch & Lomb Incorporated | Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions |
| US8064439B2 (en) | 2005-06-30 | 2011-11-22 | Cisco Technology, Inc. | Method and system for call processing |
| EP1919866A2 (en) | 2005-08-17 | 2008-05-14 | Wyeth a Corporation of the State of Delaware | Substituted indoles and use thereof |
| US8741260B2 (en) | 2005-10-07 | 2014-06-03 | Armagen Technologies, Inc. | Fusion proteins for delivery of GDNF to the CNS |
| WO2007051314A1 (en) | 2005-11-07 | 2007-05-10 | American Diagnostica Inc. | Curcuminoid compounds for inhibiting plasminogen activator inhibitor-1 |
| CN100529085C (zh) | 2005-12-30 | 2009-08-19 | 上海新生源医药研究有限公司 | 重组人纤溶酶原Kringle 5(hk5)生产方法 |
| CN101002888A (zh) | 2006-01-16 | 2007-07-25 | 陈维森 | 复方糖尿康 |
| US20070196350A1 (en) | 2006-02-22 | 2007-08-23 | Bartels Stephen P | Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment |
| WO2008026999A2 (en) | 2006-08-28 | 2008-03-06 | Omnio Healer Ab | Candidates against infection |
| US20100080773A1 (en) | 2008-09-26 | 2010-04-01 | Sdg, Inc. | Orally Bioavailable Lipid-Based Constructs |
| RU2010120675A (ru) | 2007-10-23 | 2011-11-27 | Инститьют Оф Медисинал Молекьюлар Дизайн, Инк. (Jp) | Ингибитор продуцирования pai-1 |
| JP5539896B2 (ja) | 2007-11-29 | 2014-07-02 | グリフオルス・セラピユーテイクス・インコーポレーテツド | 組換え的に改変されたプラスミン |
| US20090208448A1 (en) * | 2008-02-15 | 2009-08-20 | Solomon Keith R | Inhibition of angiogenesis |
| JP2009196927A (ja) | 2008-02-21 | 2009-09-03 | Chemo Sero Therapeut Res Inst | 血管障害に起因する網膜障害の進展阻害または治療剤 |
| WO2010125148A2 (en) | 2009-04-30 | 2010-11-04 | Catherine Blondel | Methods for treating ocular conditions |
| EP2451835A1 (en) | 2009-07-10 | 2012-05-16 | ThromboGenics N.V. | Variants of plasminogen and plasmin |
| CN102250210B (zh) | 2010-05-21 | 2014-05-28 | 厦门大学 | 人纤溶酶原Kringle 5短肽、其药物组合物、用途和编码该种短肽的多核苷酸 |
| CN102121023B (zh) | 2010-12-22 | 2012-07-04 | 中山大学 | 突变型人纤溶酶原kringle5及其制备方法及应用 |
| RU2604807C2 (ru) | 2011-01-05 | 2016-12-10 | ТромбоДженикс НВ | Варианты плазминогена и плазмина |
| CN102154253A (zh) | 2011-01-06 | 2011-08-17 | 郑州大学 | 具有抑制血小板凝集功能的微小纤溶酶原突变体及其制备方法和用途 |
| JP6000353B2 (ja) * | 2011-08-12 | 2016-09-28 | スロンボジェニックス・ナムローゼ・フェンノートシャップＴｈｒｏｍｂｏＧｅｎｉｃｓ ＮＶ | プラスミノーゲンおよびプラスミンの変異体 |
| WO2014070983A1 (en) | 2012-10-31 | 2014-05-08 | The Regents Of The University Of Michigan | Plasminogen activator-1 inhibitors and methods of use thereof |
| EA033403B1 (ru) * | 2013-08-13 | 2019-10-31 | Sanofi Sa | Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения |
| CN111879948A (zh) * | 2013-10-17 | 2020-11-03 | 综合医院公司 | 鉴定响应于用于自身免疫性疾病的治疗的受试者的方法以及用于治疗该疾病的组合物 |
| CN104789544B (zh) * | 2014-01-16 | 2019-11-26 | 中国科学院福建物质结构研究所 | 重组pai-1抑制剂、包含其的组合物及其用于治疗和检测用途 |
| PY1577621A (es) | 2014-12-19 | 2017-10-02 | Prometic Biotherapeutics Inc | Composicion farmaceutica que comprende plasminogeno y uso para el mismo |
| TWI801331B (zh) * | 2015-11-03 | 2023-05-11 | 美商波麥堤克生物治療股份有限公司 | 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法 |
| TWI624267B (zh) | 2015-12-18 | 2018-05-21 | Talengen Institute Of Life Sciences Co Ltd | 纖溶酶原在製備預防或治療糖尿病性視網膜病變的藥劑上的用途及包括纖溶酶原用於預防或治療糖尿病性視網膜病變之藥劑 |
| CN108778307A (zh) | 2015-12-18 | 2018-11-09 | 泰伦基国际有限公司 | 一种预防和治疗糖尿病肾病的方法 |
| CN115845037A (zh) | 2015-12-18 | 2023-03-28 | 泰伦基国际有限公司 | 一种用于预防或治疗急性及慢性血栓的方法 |
| TWI653981B (zh) | 2015-12-18 | 2019-03-21 | 深圳瑞健生命科學硏究院有限公司 | Use of plasminogen for the preparation of a medicament for preventing or treating a condition associated with diabetic nerve injury |
| US11129880B2 (en) * | 2016-12-15 | 2021-09-28 | Talengen International Limited | Method for promoting insulin secretion |
| TW201822805A (zh) | 2016-12-15 | 2018-07-01 | 深圳瑞健生命科學硏究院有限公司 | 一種預防和治療脂肪異常沉積導致的組織損傷的方法 |
| EP3725326B1 (en) | 2017-12-15 | 2026-04-22 | Talengen International Limited | Plasminogen for treating osteoarthritis |
-
2017
- 2017-06-19 US US16/470,120 patent/US11129880B2/en active Active
- 2017-06-19 WO PCT/CN2017/089066 patent/WO2018107706A1/zh not_active Ceased
- 2017-06-19 JP JP2019532043A patent/JP7554048B2/ja active Active
- 2017-06-19 CN CN201780078124.3A patent/CN110139667A/zh active Pending
- 2017-06-19 CA CA3047177A patent/CA3047177A1/en not_active Abandoned
- 2017-06-19 CN CN201780078168.6A patent/CN110198732A/zh active Pending
- 2017-06-19 CA CA3047176A patent/CA3047176C/en active Active
- 2017-06-19 JP JP2019532019A patent/JP7554557B2/ja active Active
- 2017-06-19 WO PCT/CN2017/089064 patent/WO2018107704A1/zh not_active Ceased
- 2017-06-19 EP EP17882072.6A patent/EP3556392B1/en active Active
- 2017-06-19 CA CA3047173A patent/CA3047173A1/en not_active Abandoned
- 2017-06-19 TW TW106120494A patent/TWI669130B/zh active
- 2017-06-19 WO PCT/CN2017/089063 patent/WO2018107703A1/zh not_active Ceased
- 2017-06-19 CN CN201780078122.4A patent/CN110366426A/zh active Pending
- 2017-06-19 US US16/470,117 patent/US20190314464A1/en not_active Abandoned
- 2017-06-19 JP JP2019532017A patent/JP7175270B2/ja active Active
- 2017-06-19 EP EP17881683.1A patent/EP3556390B1/en active Active
- 2017-06-19 US US16/469,817 patent/US11311607B2/en active Active
- 2017-06-19 WO PCT/CN2017/089065 patent/WO2018107705A1/zh not_active Ceased
- 2017-06-19 WO PCT/CN2017/089061 patent/WO2018107701A1/zh not_active Ceased
- 2017-06-19 US US16/469,845 patent/US20190307861A1/en not_active Abandoned
- 2017-06-19 TW TW106120480A patent/TWI738799B/zh active
- 2017-06-19 JP JP2019531895A patent/JP7171572B2/ja active Active
- 2017-06-19 EP EP17880561.0A patent/EP3556383B1/en active Active
- 2017-06-19 ES ES17880561T patent/ES2981141T3/es active Active
- 2017-06-19 TW TW106120484A patent/TW201822803A/zh unknown
- 2017-06-19 DK DK17880561.0T patent/DK3556383T5/da active
- 2017-06-19 WO PCT/CN2017/089062 patent/WO2018107702A1/zh not_active Ceased
- 2017-06-19 CA CA3047172A patent/CA3047172A1/en not_active Abandoned
- 2017-06-19 CN CN201780078131.3A patent/CN110121357A/zh active Pending
- 2017-06-19 TW TW106120482A patent/TWI644682B/zh active
- 2017-06-19 TW TW106120481A patent/TWI763680B/zh active
- 2017-06-19 TW TW106120485A patent/TWI642442B/zh active
- 2017-06-19 WO PCT/CN2017/089069 patent/WO2018107708A1/zh not_active Ceased
- 2017-06-19 EP EP17880563.6A patent/EP3556384B1/en active Active
- 2017-06-19 TW TW106120493A patent/TWI763681B/zh active
-
2022
- 2022-07-27 JP JP2022119582A patent/JP2022166028A/ja active Pending
- 2022-07-27 JP JP2022119543A patent/JP2022166026A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fonseca | Defining and characterizing the progression of type 2 diabetes | |
| Aschner et al. | Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial | |
| Kapitza et al. | Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin | |
| Kann et al. | Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride | |
| JP2020502151A5 (enExample) | ||
| Sakamoto et al. | Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study) | |
| Retnakaran et al. | Short‐term intensified insulin treatment in type 2 diabetes: long‐term effects on β‐cell function | |
| JP2020502150A5 (enExample) | ||
| Hanefeld | Use of insulin in type 2 diabetes: what we learned from recent clinical trials on the benefits of early insulin initiation | |
| Wysham et al. | Five-year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trial | |
| Schwartz et al. | Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes? The time has come for GLP-1 receptor agonists! | |
| Gómez-Peralta et al. | When does diabetes start? Early detection and intervention in type 2 diabetes mellitus | |
| Kothare et al. | Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus | |
| JP2020510628A5 (enExample) | ||
| Hollander et al. | Effects of taspoglutide on glycemic control and body weight in obese patients with type 2 diabetes (T‐emerge 7 study) | |
| Lu et al. | Ketosis Onset Type 2 Diabetes Had Better Islet β‐Cell Function and More Serious Insulin Resistance | |
| Jain et al. | Prandial–basal insulin regimens plus oral antihyperglycaemic agents to improve mealtime glycaemia: initiate and progressively advance insulin therapy in type 2 diabetes | |
| Ge et al. | Utility of hypoglycemic agents to treat asthma with comorbid obesity | |
| Wang et al. | Effects of basal insulin application on serum visfatin and adiponectin levels in type 2 diabetes | |
| Li et al. | Effects of saxagliptin add-on therapy to insulin on blood glycemic fluctuations in patients with type 2 diabetes: a randomized, control, open-labeled trial | |
| Kostev et al. | Effects of selected antidiabetics on weight loss–a retrospective database analysis | |
| Lv et al. | Comparison of a multiple daily insulin injection regimen (glargine or detemir once daily plus prandial insulin aspart) and continuous subcutaneous insulin infusion (aspart) in short‐term intensive insulin therapy for poorly controlled type 2 diabetes patients | |
| CN108671222A (zh) | 还原型谷胱甘肽在制备治疗1型糖尿病药物中的应用 | |
| CN108135918A (zh) | Glp-1分泌促进剂 | |
| Kalra | Basal insulin analogues in the treatment of diabetes mellitus: What progress have we made? |